Fig. 4: MTBP cancer biomarkers matching in the Cancer Core Europe cohort.
a, The MTBP matches the observed tumor variants with cancer biomarkers reported as a specific nucleotide or protein change (see examples next to the red vertical lines), a categorical genomic definition (red horizontal line examples) or a functional entity (matched according to the MTBP functional interpretation; red circle examples). Variant actionability must also factor in (among others) the coincidence between the biomarker and patient’s cancer type; the MTBP takes into account the disease hierarchy so the biomarker is matched when reported for the patient’s tumor type or a subtype thereof (red arrow). b, The MTBP ranks the cancer biomarkers (diagnosis, prognosis and drug response) found in the tumor following the ESMO/ESCAT scale22 with two minor modifications (Methods). An approximate equivalence with the actionability proposed by the Association for Molecular Pathology, American Society of Clinical Oncology and College of American Pathologists (AMP/ASCO/CAP)23 is also shown (left). The table summarizes how the MTBP classifies the biomarker actionability according to the coincidence of the (i) variant and (ii) cancer type reported for the patient’s tumor versus biomarker and (iii) the clinical evidence supporting the biomarker effect (as curated by each of the biomarker knowledge bases used by the MTBP at the moment of writing). c, Tumor mutations observed in the CCE cohort matching with drug sensitivity biomarkers (biomarkers of resistance or toxicity are not included here). Colors represent the highest level of actionability of all the biomarkers found in each tumor. Numbers above the bars represent the median (percentile 25–75) number of unique mutations per tumor reported as drug sensitivity biomarkers, regardless of their level of actionability. Cancer types are grouped by their tissue of origin.
